About us
We are physicians, scientists and chemists from Germany and Thailand. Together we make the new GLP-1/GIP/glucagon triple-agonist generation available through a Bangkok partner clinic — medically supervised, under an authorised clinical protocol and with personal care in German and English.
Obesity is a chronic, medically treatable disease. We believe: people with metabolic syndrome, insulin resistance or treatment-resistant obesity should have access to the most effective therapy available today — even before Retatrutide (LY3437943) receives regular EU approval in 2026/27. That access must be medically supervised, transparent and pharmaceutically clean.
Every treatment starts with medical history, labs and a BMI assessment by one of the team's physicians. Continuation only when medically appropriate — a clear yes/no with no sales pressure.
Batch-level HPLC/MS purity testing, documented 2–8 °C cold chain and endotoxin screening by a PhD peptide chemist — not by the seller.
We cite TRIUMPH-1 to TRIUMPH-4 and published NEJM data — not marketing claims. Side effects and contraindications are addressed explicitly.
From the German initial consult to the English follow-up in Bangkok: the same points of contact, one shared protocol, no language barriers.
Endocrinologists, obesity physicians, clinical pharmacologists and peptide chemists — every treatment is owned by named people, not by an anonymous platform.
Metabolic specialist & team lead
Bangkok, Thailand
After his master's, he specialised in the hormonal control loops of lipid metabolism. He develops practical peptide concepts for obesity care that specifically improve insulin sensitivity and regulate cravings.
Focus
GLP-1/GIP receptor analogues, metabolic weight regulation
Development biochemist
Munich, Germany
Focuses on the stability of peptide chains against enzymatic degradation in the digestive tract. She optimises formulations to convert previously injection-only fat-burning peptides (such as growth-hormone secretagogues) into stable oral dosage forms.
Focus
Peptide synthesis, galenic formulations
Molecular biologist & computational designer
Cambridge, United Kingdom
Runs software simulations of the binding affinity of signal peptides at the receptors of fat cells (adipocytes). His models ensure that the peptides in development maximise the breakdown of visceral adipose tissue while preserving muscle mass.
Focus
Receptor targeting, lipolysis control
Biochemist for cellular energetics
Bangkok, Thailand
Researches the effect of mitochondrial peptides (such as MOTS-c) on basal metabolic rate. She runs the lab screens to identify peptides that stimulate fat and glucose metabolism in skeletal muscle in a way analogous to physical exercise.
Focus
Mitochondrial activation, peptide screening
Pharmacologist & study coordinator
Berlin, Germany
Runs the monitoring and documentation of user testing. He analyses precise blood and metabolic values to guarantee the long-term safety of the peptide formulations for the cardiovascular system and liver function.
Focus
Toxicology, safety profiles, application monitoring
Treatment takes place in Bangkok under the Thai FDA (อย.) trial authorisation. Retatrutide is currently not regularly approved in Germany, Austria or Switzerland; regular EU approval is expected after TRIUMPH-1 concludes in 2026/27. We do not ship treatment to Germany and do not issue prescriptions for self-supply.
This page is for informational purposes only. It does not replace individual medical advice.
Treatment available
We offer this treatment – free initial consultation.